PACB vs. SQQQ

In the year-to-date period, PACB achieves a -79.92% return, which is significantly lower than SQQQ's -52.49% return. Over the past 10 years, PACB has outperformed SQQQ with an annualized return of -12.48%, while SQQQ has yielded a comparatively lower -52.39% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and ProShares UltraPro Short QQQ (SQQQ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current PACB Sharpe Ratio is -0.68, which is higher than the SQQQ Sharpe Ratio of -1.02. The chart below compares the historical Sharpe Ratios of PACB and SQQQ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

PACB has not paid dividends to shareholders, while SQQQ's dividend yield for the trailing twelve months is around 7.71%.

The maximum PACB drawdown since its inception was -97.65%, roughly equal to the maximum SQQQ drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for PACB and SQQQ. For additional features, visit the drawdowns tool.

Pacific Biosciences of California, Inc. (PACB) has a higher volatility of 26.23% compared to ProShares UltraPro Short QQQ (SQQQ) at 15.39%. This indicates that PACB's price experiences larger fluctuations and is considered to be riskier than SQQQ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.